A single-arm phase III study exploring the efficacy and safety of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5 mg), in an …
G Fan, S Kang, M Ren, E Weisberg, E Lukkari-Lax… - Contraception, 2017 - Elsevier
Objective The objective was to evaluate the efficacy and safety of a low-dose levonorgestrel
intrauterine system with total content 13.5 mg (average approximately 8 μg/24 h over the first …
intrauterine system with total content 13.5 mg (average approximately 8 μg/24 h over the first …
Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use
K Gemzell-Danielsson, D Apter, S Dermout… - European Journal of …, 2017 - Elsevier
Objective To evaluate the efficacy and safety of a new, low-dose levonorgestrel intrauterine
contraceptive system (LNG-IUS 12) for up to 5 years of use. Study design In this Phase III …
contraceptive system (LNG-IUS 12) for up to 5 years of use. Study design In this Phase III …
[HTML][HTML] A Phase III, single-arm study of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5 mg) in postmenarcheal adolescents
K Gemzell-Danielsson, KJ Buhling, SM Dermout… - Contraception, 2016 - Elsevier
Objective To assess the safety profile of the low-dose levonorgestrel intrauterine system
(LNG-IUS) total content 13.5 mg (average approximate release rate 8 μg/24 h over the first …
(LNG-IUS) total content 13.5 mg (average approximate release rate 8 μg/24 h over the first …
[HTML][HTML] Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system
Objective To assess 3-year data on the efficacy and safety of a new 52-mg levonorgestrel
intrauterine contraceptive (LNG20) designed for up to 7 years use. Study Design Nulliparous …
intrauterine contraceptive (LNG20) designed for up to 7 years use. Study Design Nulliparous …
[HTML][HTML] Five-year contraceptive efficacy and safety of a levonorgestrel 52-mg intrauterine system
OBJECTIVE: To assess the 5-year contraceptive efficacy and safety of a levonorgestrel
(LNG) 52-mg intrauterine system (IUS) from an ongoing 10-year phase 3 contraceptive trial …
(LNG) 52-mg intrauterine system (IUS) from an ongoing 10-year phase 3 contraceptive trial …
[HTML][HTML] The effect of age, parity and body mass index on the efficacy, safety, placement and user satisfaction associated with two low-dose levonorgestrel intrauterine …
K Gemzell-Danielsson, D Apter, B Hauck, T Schmelter… - PloS one, 2015 - journals.plos.org
Objective Two low-dose levonorgestrel intrauterine contraceptive systems (LNG-IUSs; total
content 13.5 mg [average approx. 8 μg/24 hours over the first year; LNG-IUS 8] and total …
content 13.5 mg [average approx. 8 μg/24 hours over the first year; LNG-IUS 8] and total …
A global, randomized, phase III, pearl index study comparing the efficacy and safety of two low-dose levonorgestrel-releasing intrauterine systems (LNG-IUSS) in …
A Nelson, D Apter, B Hauck, S Rybowski, K Rosen… - Fertility and …, 2012 - fertstert.org
Materials and methods Nulliparous and parous women aged 18-35 years with regular
cycles (21-35 days) requesting contraception were randomized to LNG-IUS12 or LNG …
cycles (21-35 days) requesting contraception were randomized to LNG-IUS12 or LNG …
Kyleena™(levonorgestrel-releasing intrauterine system) in contraception: a profile of its use
K McKeage, KA Lyseng-Williamson - Drugs & Therapy Perspectives, 2017 - Springer
Kyleena™ is a levonorgestrel (LNG) intrauterine system (IUS) that releases 12 μg of LNG
daily during the first year of use (LNG-IUS 12). It is the first low-dose LNG IUS approved for …
daily during the first year of use (LNG-IUS 12). It is the first low-dose LNG IUS approved for …
A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral …
L Borgatta, KJ Buhling, S Rybowski… - The European Journal …, 2016 - Taylor & Francis
Objectives: To compare user satisfaction and adverse events (AEs) with a levonorgestrel
intrauterine system (LNG-IUS 8; average levonorgestrel release rate approximately 8 μg/24 …
intrauterine system (LNG-IUS 8; average levonorgestrel release rate approximately 8 μg/24 …
Six-year contraceptive efficacy and continued safety of a levonorgestrel 52 mg intrauterine system
Objective To assess 6-year contraceptive efficacy and safety of a levonorgestrel 52 mg
intrauterine system (IUS). Study Design We assessed pregnancy rates through 72 months in …
intrauterine system (IUS). Study Design We assessed pregnancy rates through 72 months in …